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Abstract
Introduction: Prognosis of the patients with beta blocker or calcium channel blocker 
induced AV block is not well known  to date. 
Methods: All patients with symptomatic second-degree or third-degree atrioventricular 
block (AV) referred to our institution during one year were recuited prospectively and 
classified in two groups based on drug consumption (beta blocker/calcium channel 
blocker versus none). They were followed for six months and then collected data was 
analyzed.
Results: The study included 49 patients, 28 patients (age 60.1 ± 20, 19 male) did not use 
any beta blocker or calcium channel blocker (No- DU group) and other 21 patients (age 
73.5 ± 10.4, 7 male) receivd beta blocker, calcium channel blocker or both at the time 
of AV block (DU group). No-DU group was significantly younger than DU group. The 
most common atrial rhythm in both groups was sinus. There was no significant difference 
in QRS wideness or ventricular rate. AV block regressed in 43% of the DU group after 
discontinuation of drug for five half-life, but, Mobitz type 2 or complete AV block occurred 
again during six months in 50% of them without consumption of the culprit drug.
Conclusions: More than two third of the patients who developed AV block on beta 
blocker and/or calcium channel blocker needed permanent pacemaker in six months of 
follow- up, so we concluded that the development of AV block was not as benign as it 
seems in these patients.
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INTRODUCTION
According to ACC/AHA/HRS 2008 Guideline, perma-
nent pacemaker implantation is indicated for third degree 
and advanced second-degree atrioventricular block (AV) 
at any anatomic level associated with symptomatic brady-
cardia or ventricular arrhythmias presumed to be due to 
AV block and also is indicated in symptom-free patients in 
sinus rhythm, with documented periods of asystole great-
er than or equal to 3.0 seconds, any escape rate less than 
40 beat per minute (bpm), or with an escape rhythm that 
is below the AV node (class I) [1]. However, pacemak-
er implantation is generally considered unnecessary if it 
caused by reversible etiologies such as electrolyte abnor-
malities [1].
It is documented that drugs such as calcium channel 
blockers and beta blockers, prolong AV nodal conduction 
and refractoriness in humans may cause AV block [2, 3]. 
But since the significant bradycardia is rare with therapeu-
tic doses in normal heart [4], one of the theories can be 
unmasking of underlying AV node or hiss-purkinje diseas-
es caused by these medications. So prognosis and natural 
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METHODS
This prospective study was designed for assessment of mid 
term prognosis in patients with drug induced AV block. 
The study protocol was reviewed, and approved by the Re-
view Board of Shaheed Rajaei Cardiovascular Medical and 
Research Center, and Iran  University of Medical Sciences 
High Research Council. All patients with symptomatic sec-
ond-degree or third-degree AV block  referring to our institu-
tion between April 2010 and April 2011 were prospectively 
collected. Patients with concomitant myocardial infarction, 
electrolyte abnormalities, digitalis toxicity, vasovagal synco-
pe, and those taking class I or III antiarhythmics were exclud-
ed.
The type of AV block was determined by the surface electro-
cardiogram (ECG). Patients were classified into two groups 
to define a relationship between beta-blocker or calcium 
channel blocker therapy and AV block: (1) patients who 
developed AV block in the absence of drugs that affect AV 
conduction (No-DUgroup), (2) patients in whom AV block 
occurred on beta-blockers or calcium channel blockers ther-
apy (DU-group).
Patients in group 2 were subclassified as follows: (1) patients 
in whom AV block resolved after the discontinuation of drug 
after 5 half-life (Soon-AVB-R) (2) patients in whom AV 
block was not resolved and persisted in spite of discontinu-
ation of drug (Soon-AVB-NR).
All patients were monitored continuously during their hos-
pitalization course until they had improved AV conduction 
within 4-6 days or received an implanted pacemaker (if AV 
block did not resolve). Patients with apparently normal AV 
conduction after discontinuation of drug, were discharged 
and recommended to visit arrhythmia clinic, for evaluation 
of AV conduction with surface ECG. Patients who had pace-
maker placement have been followed in pace maker clinic on 
a regular basis.
Permanent pacemaker was implanted for all of the patients 
with recurrence of AV block during follow-up. Collection and 
analysis of data were authorized by the ethics committee of 
the hospital. Data were expressed as mean ± SD. Student’s T 
test, Chi square test and Fisher’s exact probability test were 
used to analyze the data. Results were considered significant 
at an error probability level of P < 0.05.
RESULTS
Twenty eight of 49 patients who met the criteria and entered 
the study, didn’t use any beta blocker or calcium channel 
blocker (No-DU group). Mean age of this group was 60.1 ± 
20 years, 32.1% were female and 67.9% were male (Table 1).
Other 21 patients with mean age of 73.5 ± 10.4 years (66.7% 
female; 33.3% male) were receiving beta blocker (81%), 
calcium channel blocker (9.5%) or both (9.5%) at the time 
of AV block (DU group). This group was significantly older 
than No-DU group (P = 0.04) and dominantly was female (P 
= 0.02) (Table 1).
Although Sinus rhythm was the most common atrial rhythm 
in both No-DU and DU patients (92.9% and 95.2%, respec-
tively), the degree of AV block seemed to be some what dif-
ferent in both groups. In No-DU group, no patient had Mo-
bitz type I (Wenckebach) AV block, 7.1% had Mobitz type 
2, and 92.9% had 3rd degree AV block compared to 4.8, 33.3 
and 61.9 in DU group, respectively. QRS duration and also 
ventricular rate were not significantly different between both 
groups (Table 1).
Follow-up after Five Half Life of Drug
AV block regressed in 43% (9 of 21) of the DU patients with 
discontinuation of drug after 5 half life (Soon-AVB-R). Mean 
age of this subgroup was 69.7 ± 10 years (55.6% female; 
44.4% male).The remained 57% patients whose AV blocks 
persist in spite of discontinuation of drug (Soon-AVBNR) 
candidate for permanent pacemaker implantation. The mean 
age of this subgroup was 76.4 ± 10 years (75% female; 25% 
male) which was not significantly different from previous 
subgroup. Analysis of these two subgroups didn’t show any 
significant differences in degree of AV block, QRS duration, 
and ventricular rate (Table 2).
Table 1: Comparison Between the Patients Who Were on Medication and Who Weren’t on Medication at the Time of Atrioventricular 
Block
 AV Block During Drug
Therapy, (n = 21)
 AV Block Without
Drugs, (n = 28)
P Value
Age (y) 73.5 ± 10.4 60.1 ± 20 0.04
Male Gender 7 (33.3) 19 (67.9) 0.02
Sinus rhythm 20 (95.2) 26 (92.9) 1.0
Level of block 0.01
Wenckebach 1 (4.8) 0 (0)
Mobitz type 2 7 (33.3) 2 (7.1)
Complete AV block 13 (61.9) 26 (92.9)
QRS duration > 120 msec 12 (57.1) 10 (35.7) 0.16
Ventricular rate < 40 bpm 13 (65) 22 (78.6) 0.34
Data are presented as mean ± SD and No. (%).
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Table 2: Characteristic of the Patients with AV Block on Medication after Discontinuation of Drug for 5 Half Life
AV Block Regressed after Discon-
tinuation of Drug, (n = 9)
AV Block Remained after Dis-
continuation of Drug, (n = 12)
P Value
Age (y) 69.67 ± 10 76.42 ± 10 0.14
Male Gender 4 (44.4) 3 (25) 0.40
Level of block 0.79
Wenckebach 0 (0) 1 (8.3)
Mobitz type 2 4 (44.4) 3 (25)
Complete AV block 5 (55.6) 8 (66.7)
QRS duration > 120 msec 4 (44.4) 8 (66.7) 0.40
Ventricular rate < 40 bpm 4 (44.4) 4 (33.3) 0.67
Data are presented as mean ± SD and No. (%).
Table 3: ECG Characteristics of the Patients Who Were on Medication at the Time of Atrioventricular Block after a 6-month Follow-up
 Drug User-Drug Related AV
Block *
(n = 4)
 Drug User-Non-Drug Related
AV Block **
 (n = 16)
P Value
QRS duration>120msec 2 (50) 10 (62.5) 0.64
Ventricular rate< 40 bpm 2 (50) 4 (26.7) 0.32
*Patients with AV block during drug consumption whose AV block regressed with discontinuation of medication and didn’t relapse in six- 
months of follow- up
**patients with AV block during drug consumption whose AV block didn’t regressed or relapse in six moths of follow - up despite the dis-
continuation of drug.
Data are presented as No. (%).
A Six-month Follow-up
In a six-month follow-up, one of the cases missed, in Soon-
AVB-R group, 50% developed Mobitz type 2 or complete AV 
block that needed permanent pacemaker implantation. On 
the other side, 8.3% (one case) of the Soon-AVB-NRs in the 
absence of drug therapy (with betablocker and/or calcium 
channel blocker) and 3.6% (one case) of No-DUs showed 
disappearance of AV block and restoration of sinus rhythm 
in follow up. (Table 3)
If we pool all the patients with AV block during drug con-
sumption who needed permanent pacemaker implantation 
till six months of follow-up as drug users, not drug related AV 
block group (DU-NDR), and who didn’t need permanent 
pacemaker implantation as drug users, drug related group 
(DU-DR), and compare them, again there will be no signif-
icant differences according to QRS duration or ventricular 
rate.
DISCUSSION
In our study, most of the patients with AV block in No-DU 
was male, but most of the patients in DU was female. This 
can be concluded that increasing female consuming beta 
blockers or calcium channel blocker or these kinds of drugs 
results in increasing AV blocks. However, the main finding of 
our study was that nearly one half of the patients admitted 
in the hospital due to AV block (except those caused by di-
goxin toxicity, myocardial infarction, electrolyte imbalance 
and vasovagal response) was on beta blocker and/or calcium 
channel blocker. Drugs were discontinued in all of these pa-
tients, but in 43% of them, AV block didn’t regress, and in 
50% of them AV block resolved, relapse was seen in less than 
six months. So it seems that about 70% of patients who was 
on beta blocker and/or calcium channel blocker at the time 
of AV block, permanent pacemaker was needed in six months 
of follow-up.
There are few other studies with the same result [5, 6]. A re-
cent study reported that only 15% of AV blocks in patients 
treated with beta-blockers and/or calcium channel blocker, 
is truly caused by these drugs and in others, drug was only 
‘innocent bystanders’ [5]. The authors concluded that as the 
effect of these drugs is slowing down the conduction of SA 
node and AV node and this would decrease conduction block 
in infra- nodal pathways, so in these patients, infra- nodal con-
duction disease expected to be more severe. In our study, we 
couldn’t find any relationship between QRS duration or ven-
tricular rate (as signs of supranodal or infra -nodal disease) 
[7-9] and AV block in drug users; in other word, ECG finding 
of supra or infra nodal block is not a predictor of permanent 
pacemaker requirement in patients who consumes drug and 
are on AV block.
Another study that assessed the prognosis of bradycardia 
related to drugs, evaluated 38 patients with symptomatic 
bradycardia during beta blocker or calcium channel blocker 
consumption, and showed that in 10 of 38 cases, bradycardia 
were not caused by drugs, but were revealed by drugs [10]. 
Interestingly, in this study, if we omit cases with AV block 
from that 31 patients who came with symptomatic sinus bra-
dycardia, 27(87%) patients with bradycardia will be resolved 
by discontinuation of drugs [10].
Comparing these studies, one can argue when a patient re-
ferred due to symptomatic bradycardia on beta blocker or 
calcium channel blockers, if the bradycardia is caused by the 
second or third degree AV block, it is less probably that the 
drug induces and if it is caused by sinus bradycardia it is most 
probably that the drug induces and will regress by discontin-
uation of drug.
Study limitation: 1) We studied 49 cases prospectively and 
this limited numbers of patients prevent subgroup analysis. 
So some important features such as the effect of drug dose, 
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which may be a predictor of reversibility, were not evaluated 
in this study. 2) Although most of the clues in this and previ-
ous studies are compatible with infra -nodal disease of cases 
who developed AV block on beta blocker or calcium channel 
blocker, the studies on electrophysiology is needed.
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